Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation.
OBJECTIVE
The aim of the present study was to quantitatively monitor the response of CD95 molecules expressed on CD3(+) T cells (CD95(+)CD3(+) cells) and CD38 molecules expressed on CD8(+) T cells (CD38(+)CD8(+) cells) to ganciclovir treatment after orthotopic liver transplant (OLT) in recipients with active human cytomegalovirus (HCMV) infection.


METHODS
Blood samples were collected from 20 liver transplanted recipients with active HCMV infection and 24 recipients without HCMV infection. CD95(+)CD3(+) cells and CD38(+)CD8(+) cells were quantitatively detected with QuantiBRITE bead methods by dual-color flow cytometry analysis during the post-transplantation period.


RESULTS
CD95(+)CD3(+) cells and CD38(+)CD8(+) cells were not significantly different among different ages of healthy adults (P > 0.05). CD95(+)CD3(+) cells and CD38(+)CD8(+) cells were drastically increased in the active HCMV infection group compared with that in the stable group or in the healthy group (P < 0.001), and then they were gradually decreased within the next several weeks after ganciclovir treatment when compared with active HCMV infection recipients (P < 0.001).


CONCLUSIONS
The present study showed that CD38(+)CD8(+) T cells can be an appropriate immunological marker for early detection and antiviral therapeutic monitoring of HCMV infection. The evaluation of CD95 molecule levels may be used routinely in clinical practice to assess the level of immunosuppression.
Wang
Yuliang
Y
Tianjin Institute of Urology, Tianjin Medical University, Hexi District, Tianjin, China.
Liu
Yawu
Y
Han
Ruifa
R
Li
Qiang
Q
Yao
Zhi
Z
Niu
Wenyan
W
Yuan
Yuhua
Y
Tang
Zhiqin
Z
Zhu
Zhijun
Z
Shen
Zhongyang
Z
D051997:ADP-ribosyl Cyclase 1 / Q000097:blood*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D017252:CD3 Complex / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D016022:Case-Control Studies; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005434:Flow Cytometry; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D013997:Time Factors; D016896:Treatment Outcome; D019014:fas Receptor / Q000097:blood*
D000998:Antiviral Agents; D015415:Biomarkers; D017252:CD3 Complex; C491901:FAS protein, human; D008562:Membrane Glycoproteins; D019014:fas Receptor; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D015774:Ganciclovir